

Things to Know about the DE CTR ACCEL Program



ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH












ACCEL Program Overview

Work supported by an <u>Institutional Development Award</u> (**IDeA**) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number U54-GM104941 (PI:Hicks) and the State of Delaware.



IDeA Program





The Institutional Development Award (IDeA) is a congressionally mandated program that builds research capacity in states that historically have had low levels of NIH funding. It supports competitive basic, clinical, and translational research, faculty development, and infrastructure improvements. The program aims to strengthen an institution's ability to support biomedical research, enhance the competitiveness of investigators in securing research funding, and enable clinical and translational research that addresses the needs of medically underserved communities.

IDeA-eligible states include: Alaska, Arkansas, Delaware, Hawaii, Idaho, Kansas, Kentucky, Louisiana, Maine, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, Wyoming, and Puerto Rico



Information about the IDeA Program



This interactive dashboard provides data surrounding funding and other resources for IDeA mechanisms

IDeA Interactive Portfolio Dashboard (nih.gov)



IDeA Funding



269 total awards \$420,802,961 total awarded dollars \$416,059,258 IDeA total awarded dollars



SUB-PROGRAM	Award Count	Total Dollars	IDeA Total Dollars
IDeA - COBRE	149	\$253,528,990	\$253,528,990
IDeA - INBRE	21	\$71,963,512	\$71,963,512
IDeA - CTR	13	\$52,586,270	\$52,586,270
IDeA - Co-Funding	77	\$34,558,844	\$34,558,844
IDeA - Regional Entrepreneurship Development (I- RED) Program	4	\$4,743,703	\$0
IDeA - Other Research	5	\$3,421,642	\$3,421,642

ACCEL on interactive dashboard



Project	♦ PI	Institution	♦ FY ♦	Cong Dist	Total Dollars
2U54GM104941-11	HICKS, GREGORY E	UNIVERSITY OF DELAWARE	2023	DE-00	\$4,000,000
3U54GM104941-11S3	HICKS, GREGORY E	UNIVERSITY OF DELAWARE	2023	DE-00	\$90,315
3U54GM104941-11S2	HICKS, GREGORY E	UNIVERSITY OF DELAWARE	2023	DE-00	\$209,109
5U54GM138062-03	KAHOLOKULA, JOSEPH KEAWE'AIMOKU	UNIVERSITY OF HAWAII AT MANOA	2023	HI-01	\$3,000,000
<u>5U54GM104940-08</u>	KIRWAN, JOHN P.	LSU PENNINGTON BIOMEDICAL RESEARCH CTR	2023	LA-06	\$4,000,000
3U54GM104940-08S1	KIRWAN, JOHN P.	LSU PENNINGTON BIOMEDICAL RESEARCH CTR	2023	LA-06	\$775,741
<u>3U54GM104940-08S2</u>	KIRWAN, JOHN P.	LSU PENNINGTON BIOMEDICAL RESEARCH CTR	2023	LA-06	\$346,705



DE CTR ACCEL FUNDING Sources





lational Institute of General Medical Sciences: Contributes ~ \$4M in funding each year (inclusive of F&A)

Additional Support from:

- State of Delaware (\$1.5M/year)
- University of Delaware (F&A return)
- ChristianaCare Health Services, Inc. (F&A return)
- Delaware State University (F&A return)
- Nemours Children's Health (F&A return)

AWARD Information



- This is a cooperative agreement structure which requires NIH participation through quarterly Steering Committee* meetings in Year 11, and annually in Yrs 12-15.
- UD is prime/lead institution and ChristianaCare, Delaware State University and Nemours Children's Health subcontract to UD
- UD is required to follow all NIH rules and regulations, as are all partner institutions

^{*}Steering Committee members: 4 Site PIs, PI/PD, UD Research Official and NIH Official.

AWARD Information



- Each award year ends on June 30th
 - Unused federal funds become restricted
 - Carryover of these unused funds is not automatic, prior approval is required
 - ACCEL may request to use these funds in subsequent years
 - If awarded, they have to be utilized within the awarded grant year period
 - Cannot be requested for initiatives already budgeted

Annual closeout



- ACCEL is required to complete an annual closeout within 120 days of June 30th and submit an FFR (Federal Financial Report).
 - Subawards must submit a FINAL invoice (subrecipient closeout form) no later than 60 days past June 30th so UD can meet this deadline. Final technical reports (RPPR) are due in March each year.
 - The FFR must be approved before a carryover request for funds from the current year is considered.
 - Also, the annual RPPR must be approved by our NIGMS Program Officer prior to the NOA for the upcoming award year being issued.





- NIH rules state that Principal Investigators (<u>PI/MPI</u>) of CTR projects may not have concurrent <u>research</u> funding from another IDeA mechanism (COBRE, INBRE) as a PI, but PIs are eligible for IDeA funding as a co-I.
- There cannot be scientific overlap between a CTR project and another NIHfunded project.
- Federal funding rules are applied to state funds also. If an expense is not allowable on federal, we don't allow it on state funds either.
- NIH salary cap for effort applies to both federal and state funds.



- All expenses allocated to our award must be specific to ACCEL CTR activities only and must be backed up with receipts. (i.e. computers)
- Food should never be on the federal award- always expense to iMatch/institutional funds.
- Subcontractors vs consultants on the DE CTR
 - located in IDeA states vs located in non-IDeA states

	Subcontract Characteristics	Contractor Characteristics
spon Bear Is acc Must	orms substantive programmatic work related to the asored award. s responsibility for programmatic decision making. countable for measurable performance requirements. t adhere to compliance requirements specified by asored award.	 Provides goods or services which are ancillary to the sponsored award operations. Normally operates in a competitive environment. Provides similar goods or services to many different purchasers. Is not subject to compliance requirements of the sponsored award.





NIH Grants Policy Statement

Subcontract: Can work with IDea states only.

A formalized agreement whereby a research project is carried out by the recipient and one or more other organizations that are <u>separate legal entities</u>. Under the agreement, the recipient <u>must perform a substantive role in the conduct of the planned research</u> and not merely serve as a conduit of funds to another party or parties. These agreements typically <u>involve a specific level of effort from the consortium organization's PD/PI and a categorical breakdown of costs, such as personnel, supplies, and other allowable expenses, including <u>F&A costs</u>. The relationship between the recipient and the collaborating organizations is considered a subaward relationship.</u>

Negotiated arrangements for <u>meeting the scientific, administrative, financial, and reporting requirements of the grant</u>, including those necessary to ensure compliance with all applicable Federal regulations and policies and facilitate an efficient collaborative venture.





NIH Grants Policy Statement

Consultant: Can work with IDeA and non-IDeA states

An <u>individual who provides professional advice or services for a fee</u>, but normally not as an employee of the engaging party. In unusual situations, an individual may be both a consultant and an employee of the same party, receiving compensation for some services as a consultant and for other work as a salaried employee. To prevent apparent or actual conflicts of interest, recipients and consultants must establish written guidelines indicating the conditions of payment of consulting fees. Consultants also include firms that provide professional advice or services

Adequacy of the contractual agreement for the service (e.g., description of the service, estimate of time required, rate of compensation, and termination provisions).

•

Data Requests




ACCEL is required to submit data to NIGMS annually in an RPPR (Research Performance Progress Report)

- -All CTR funded investigators are required to keep their <u>FULL PROFILE</u> current in the ACCEL dashboard and are required to confirm the profile has been updated.
- -ACCEL profiles must be linked to ORCID, instructions found at: https://www.de-ctr.org/wp-content/uploads/2020/08/DE-CTR-ORCID-iD-1.pdf (Chrome browser recommended)
- -RPPRs require all products, presentations and publications (citation details to follow) to be reported along with:
 - -Details on submitted proposals for prior 12 months (whether funded or not)
 - -Details on new and continuing current funding
 - -Details on study sections, including name of panel, location and dates

FULL PROFILE access




Here's an example of where to access your profiles on the website dashboard and how to update of your FULL PROFILE



Complete all profiles but FULL is for RPPR data needs



You will have access to any profile, but especially your FULL PROFILE on the left hand side of the page from the Profiles Menu



NIH Public Access Policy- two part process



NIH requires that publications supported by federal funds are made available free to the public within 12 months of publication. PMC is the free access repository.

The Public Access policy applies to any manuscript that:

- -Is peer-reviewed;
- -And, is accepted for publication in a journal² on or after April 7, 2008³;
- -And, arises from:

Any direct funding⁴ from an NIH grant or cooperative agreement active in Fiscal Year 2008 or beyond, or;

Any direct funding from an NIH contract signed on or after April 7, 2008, or;

Any direct funding from the NIH Intramural Program, or;

An NIH employee

1) Please make sure the publishers are citing the grant U54GM104941 and the manuscript (either journal version or final peer reviewed version) is submitted to PubMed Central and has a PMCID #.

```
****AND****
```

- 2) All ACCEL authors should add the ACCEL award number to their publications in MyNCBI (Bibliography) under
- >Manage citations
- > Click on the + award button (below the specific citation) to add an award (search for U54GM104941)

Delaware CTR ACCEL Contacts



- Dr. Gregory Hicks, Overall PI, Director and Admin Core Lead (ghicks@udel.edu)
- Dr. Susanne Morton, Program Coordinator and UD CTR Site PI (smmorton@udel.edu)
- Dr. Megan Wenner, CTR Pilot Projects Program Lead (mwenner@udel.edu)
- Robyne Nizer, CTR Grants Analyst, UD RO (rnizer@udel.edu)
- Karen Hough, CTR Program Administrator (khough@udel.edu)
- Jeanne Warrington, CTR Liaison (jeannekw@udel.edu)
- Dr. Alfred "Brud" Bacon, ChristianaCare CTR Site PI (ABacon@Christianacare.org)
- Christine Cowan, ChristianaCare CTR Financial Administrator (CCowan@Christianacare.org)
- Debra Reese, ChristianaCare CTR Program Manager (Debra.Reese@Christianacare.org)
- Dr. Sangeeta Gupta, DSU CTR Site PI (sgupta@desu.edu)
- Dayna Littleton, DSU CTR Administrator (dlittleton@desu.edu)
- Dr. Rodney Scott, Nemours CTR Site PI (Rodney.Scott@nemours.org)
- Ranita Chakrabarti, Nemours CTR Financial Administrator (Ranita.Chakrabarti@nemours.org)

Share your work!



We want to share your accomplishments, publications, awards, and funding announcements!

When you ...


- Publish your work
- Conduct a presentation about your research
- Interview with a media outlet about your research/findings
- Receive an award for your work
- Receive another grant/funding to further your research
- Have anything awesome to share with ACCEL and the community

But WHY should I share? WIN-WIN!

- Your name, research and accomplishments are shared with fellow researchers, the community and spread across social media channels/internet
- ACCEL gets more/better content on our website and social media channels that demonstrates the impact of ACCEL's work, and the program's success

Social Media Manager:
Send to our Communications Team at
Connect@de-ctr.org





Internal Advisory Committee Members





Miguel Garcia-Diaz, PhD VP Research, Scholarship and Innovation University of Delaware



Gwen Angalet, PhD
Chair
ACCEL Community Advisory
Council



Vicky Funanage, PhD
CHAIR
Professor Emerita, Nemours Children's
Health



Bethany Hall-Long, RN, PhD Lt. Governor State of Delaware



Omar Khan, MD
Enterprise Chief Scientific Officer,
ChristianaCare Health Services, Inc.
President and CEO, Delaware
Health Sciences Alliance



Melissa Harrington, PhD
Vice President for Research
Delaware State University



Matthew M. Davis, MD MAPP Executive Vice-President, Enterprise Physician-in-Chief and Chief Scientific Officer Nemours Children's Health